Latest news

• NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

  According to NICE, Ibrance now joins two other of its approved drugs – Novartis’ Kisqali (ribociclib) and Lilly’s Verzenio (abemaciclib) - as a treatment option for patients at this stage of the

• Novartis highlights emerging assets and late-stage pipeline at R&D day

  It also has plans to expand wet AMD therapy  Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments  Piqray (alpelisib) and  Kisqali(ribociclib) into additional indications to help drive growth.

• Lilly boosted by survival data for key growth drug Verzenio

  However, shortly after the top-line data were announced, Novartis reported results with a trial of its rival CDK4/6 inhibitor Kisqali (ribociclib) which stole some of Lilly’s thunder. ... Results from the MONALEESA-3 in post-menopausal women with

• Novartis raises 2019 guidance as new products gather speed

  from new prostate cancer therapy Lutathera, Kisqali (ribociclib) for breast cancer and CAR-T Kymriah (tisagenlecleucel).

• Kisqali combination follows Verzenio onto Cancer Drugs Fund

  Drug must prove its value via managed access route. Novartis’ Kisqali has been recommended for use on the Cancer Drugs Fund (CDF) for second line use in combination with fulvestrant in ... Ibrance and Kisqali gained NICE approval for first line